<a href="https://laohu8.com/S/LTRN">Lantern Pharma Inc.</a> Announces Promising Results from HARMONIC Trial as Lung Cancer Patient Achieves Durable Complete Response with LP-300
Lantern Pharma Inc. (NASDAQ: LTRN) has announced notable clinical observations from its Phase 2 HARMONIC™ clinical trial. A 70-year-old patient with advanced non-small cell lung cancer (NSCLC), who has never smoked, has achieved a durable complete response in their target cancer lesions following treatment with LP-300 in combination with standard-of-care chemotherapy. This patient continues to show sustained survival benefits nearly two years after the treatment. LP-300, developed using Lantern's proprietary RADR® AI platform, is being evaluated for its therapeutic potential in never-smokers with advanced NSCLC who have progressed after treatment with tyrosine kinase inhibitors. Results from this study have already been presented, showing promise for LP-300 as a treatment option in this patient population.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250616197862) on June 16, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。